- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Abbreviated New Drug Applications and 505(b)(2) Applications
Third Quarter
This Generic Launches chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated New Drug Applications and 505(b)(2) Applications.
Reference Listed Drug | ANDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Xyrem | Jazz | sodium oxybate | Amneal | Used to treat cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy | 7/3/2023 |
Ganirelix | Organon | ganirelix acetate | Fresenius Kabi | Used to inhibit premature surges in luteinizing hormone, or LH, a chemical in the body that triggers reproductive processes such as ovulation; used to treat women who are undergoing controlled ovarian hyperstimulation | 7/10/2023 |
Aczone | AbbVie | dapsone | Cosette | Used for the topical treatment of acne vulgaris | 7/13/2023 |
Cubicin | Cubist | daptomycin | Camber | Used to treat complicated skin and skin structure infections (cSSSI) in adult patients and pediatric patients (1 to 17 years of age) | 7/27/2023 |
Symbicort | AstraZeneca | budesonide / formoterol fumarate dihydrate | Viatris | Used in certain patients to treat asthma or chronic obstructive pulmonary disease (COPD) | 7/31/2023 |
Duexis | Horizon | ibuprophen / famotidine | Camber | Used to (1) relieve signs and symptoms of rheumatoid arthritis and osteoarthritis and (2) decrease the risk of developing upper gastrointestinal ulcers, in patients who are taking ibuprofen for those indications | 8/1/2023 |
Sabril | Lundbeck | vigabatrin | Upsher-Smith | Used for infantile spasms in patients 1 month to 2 years of age and Refractory Complex Partial Seizures (CPS) in adults and children 2 years and older with refractory complex partial seizures (CPS) | 8/1/2023 |
Gadavist | Bayer | gadobutrol | Fresenius Kabi | Used as a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI) | 8/8/2023 |
Luxiq | Mylan | betamethasone | Xiromed | Used to relieve inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp | 8/2/2023 |
Cardura | Viatris | doxazosin mesylate | Apotex | Used to treat high blood pressure (hypertension) and symptoms of an enlarged prostate (benign prostatic enlargement) | |
Toradol | Roche | ketorolac tromethamine | Camber | Used for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting | 8/7/2023 |
Mozobil | Genzyme | plerixafor | Fresenius Kabi | Used in combination with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma or multiple myeloma | 8/9/2023 |
Jadenu Sprinkle | Novartis | deferasirox | Camber | Used to treat chronic iron overload (1) due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older, and (2) in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes exhibiting elevated liver and serum iron concentrations | 8/8/2023 |
Spiriva HandiHaler | Boehringer Ingelheim | tiotropium bromide | Lupin | Used to treat chronic obstructive pulmonary disease (COPD) | 8/16/2023 |
Pepcid | Johnson & Johnson | famotidine | Upsher-Smith | Used to treat active duodenal ulcer, active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy | 8/15/2023 |
Balcoltra | Avion | levonorgestrel / ethinyl estradiol | Xiromed | Used as an oral contraceptive | 8/17/2023 |
Apriso | Valeant | mesalamine | Upsher-Smith | Used to treat and prevent flare-ups of mild to moderately active ulcerative colitis (an inflammatory bowel disease) | 8/21/2023 |
Zetia | Organon | ezetimibe | Hetero | Used to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin); reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate; reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin; reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia) |
8/24/2023 |
Alphagan | AbbVie | brimonidine tartrate | Apotex | Used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension | 9/2/2023 |
Aubagio | Sanofi | teriflunomide | Apotex | Used to treat the relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease | 9/6/2023 |
Zyprexa | Eli Lilly | olanzapine | Camber | Used to treat acute agitation associated with schizophrenia and bipolar I mania | 9/25/2023 |
Rozerem | Takeda | ramelteon | Ziromed | Used to treat insomnia characterized by difficulty with sleep onset | 9/29/2023 |
GENERICally Speaking Hatch Waxman Bulletin
GENERICally Speaking Hatch Waxman Bulletin
READ MORE Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.